Grant Life Sciences gets IP boost for cervical cancer blood test
This article was originally published in Clinica
Executive Summary
Moving forward with development plans for its cervical cancer blood test, US firm Grant Life Sciences (GLS) has secured key intellectual property covering the product's fundamental technology. The test, which is currently undergoing validation studies, promises to offer a more reliable alternative to the Pap smear.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.